Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
31 Octobre 2022 - 12:00PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it will report its financial results for the third quarter of
2022, on Monday, November 7, 2022, before the U.S. financial
markets open. The Company will host a conference call and webcast
at 8:30 a.m. ET to discuss its third quarter 2022 financial results
and provide a business update.
To join the live call to ask questions, please register here. A
dial in and unique PIN will be provided to join the call.
An audio-only webcast of the call may be accessed in the
Investors section of the Company’s website at
www.concertpharma.com. A replay of the webcast will be available on
Concert’s website for three months.
About Concert
Concert Pharmaceuticals is a late-stage clinical
biopharmaceutical company that is developing deuruxolitinib
(CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has
successfully completed two Phase 3 trials with deuruxolitinib in
adults with alopecia areata, a serious autoimmune dermatological
disease. The Company is also evaluating the use of deuruxolitinib
in other indications and assessing a number of earlier-stage
pipeline candidates. For more information, please visit
www.concertpharma.com or follow us on Twitter, Instagram or
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005054/en/
Justine Koenigsberg (781) 674-5284 ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Concert Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Concert Pharmaceuticals Inc